Wechselwirkungen · Emselex
Emselex 7.5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-113073 · Präparat HOS-093835
Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of the enzyme CYP2D6. Caution should be exercised when darifenacin is used concomitantly with medicinal products that are predominantly metabolised by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine, or tricyclic antidepressants such as imipramine. The effects of darifenacin on the metabolism of CYP2D6 substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flecainide (HOS-086203) imipramine (HOS-085907) thioridazine (HOS-086281)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 51bd776005786170df52a4057e481010570058884c6858cd42eefbfc6965c54d · Zeichen 2192–2738 im Abschnitt